AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GT Biopharma, Inc. Director's Dealing 2016

Mar 2, 2016

35496_dirs_2016-03-02_9b54352e-2c2b-4598-abbb-c4b6d3f91013.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OXIS INTERNATIONAL INC (OXIS)
CIK: 0000109657
Period of Report: 2016-02-09

Reporting Person: BRISTOL INVESTMENT FUND LTD (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common stock	2563689	Direct

Footnotes

F1: This total includes: (i) 2,232,778 shares held by Bristol Investment Fund, Ltd. ("Bristol Investment") and (ii) 330,911 shares held by Bristol Capital, LLC ("Bristol Capital"). Paul Kessler, as Director of Bristol Investment and Manager of Bristol Capital, has voting and dispositive power over the shares beneficially owned by Bristol Investment and Bristol Capital.